OCA
GLUE icon

Octagon Capital Advisors’s Monte Rosa Therapeutics GLUE Stock Holding History

Octagon Capital Advisors’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-812,895
Closed -$3.89M – 38
2023
Q3 		$3.89M Buy
812,895
+792,995
+3,985% +$5.11M 0.6% 30
2023
Q2 		$136K Buy
+19,900
New +$129K 0.02% 41
2022
Q1 		– Sell
-150,000
Closed -$3.06M – 28
2021
Q4 		$3.06M Hold
150,000
– – 0.6% 22
2021
Q3 		$3.34M Sell
150,000
-88,045
-37% -$2.52M 0.82% 25
2021
Q2 		$5.4M Buy
+238,045
New +$4.85M 1.12% 23

Other funds holding GLUE

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Octagon Capital Advisors's GLUE Position: Q4 2023 in Review

Octagon Capital Advisors sold out of Monte Rosa Therapeutics (GLUE) in Q4 2023, closing a stake of 812,895 shares — an estimated $3.89M sold.

Octagon Capital Advisors first reported a position in GLUE in Q2 2021 and held it in 5 quarters. The position peaked at $5.4M in Q2 2021. 71 funds tracked by Wall St. Rank hold GLUE as of Q4 2023.

  • Octagon Capital Advisors reported no remaining Monte Rosa Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Octagon Capital Advisors sold 812,895 Monte Rosa Therapeutics shares in Q4 2023, an estimated $3.89M.
  • Octagon Capital Advisors first reported a position in Monte Rosa Therapeutics in Q2 2021 and held it in 5 quarters.
  • Octagon Capital Advisors's Monte Rosa Therapeutics position peaked at $5.4M in Q2 2021.
  • 71 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q4 2023.

Based on Octagon Capital Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.